Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

NCT02766348 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: gemcitabine
BIOLOGICAL: DC-CTL
DRUG: cisplatinum

Sponsor

Shenzhen Hornetcorn Bio-technology Company, LTD